Adrian S. Dobs, MD, MHS
Professor of Medicine and Oncology
Johns Hopkins University School of Medicine
Division of Endocrinology and Metabolism
Baltimore, Maryland

Abraham Morgentaler, MD
Associate Clinical Professor
Urologic Surgery
Harvard Medical School
Founder, Men's Health Boston
Boston, Massachusetts

This educational activity is intended to educate urologists, primary care physicians, endocrinologists, cardiologists, specialists, and other healthcare providers interested in the management and treatment of hypogonadism and related comorbidities.

Hypogonadism is an underdiagnosed and therefore undertreated condition of men that can be associated with serious comorbid conditions, including cardiometabolic disease and osteoporosis. Despite a growing body of evidence reinforcing the safety of testosterone therapy, persistent concerns about the relationship between testosterone and the prostate continue to impede the treatment of hypogonadism. Preliminary studies have investigated the role of testosterone therapy in patient populations for whom it was once not considered. Low testosterone is associated with low bone mineral density and increased all-cause and cardiovascular mortality, as demonstrated in various epidemiologic studies. Clinicians who see men at risk for hypogonadism should be aware of the importance of screening, diagnosis, and treatment. Physicians also need to be informed about how to ensure safety with testosterone formulations and how to educate patients to optimize safety and efficacy of testosterone therapy. Safety and adherence should be assessed during regularly scheduled follow-up visits, with clinicians communicating with patients and their partners about routines and behaviors to improve adherence, create realistic expectations, and optimize treatment outcomes.

At the conclusion of this activity, participants should be better able to:

  1. Appropriately screen men seeking treatment for hypogonadism for related comorbidities, including osteoporosis, urologic conditions, and cardiometabolic disease
  2. Recognize the importance of keeping the partner involved throughout the treatment continuum when managing men's health concerns
  3. Examine with the patient the formulation-specific profile of each testosterone formulation when assessing which will best match his needs, thus ensuring adherence
  4. Assess the patient's treatment response through routine monitoring
  5. Integrate hypogonadism treatment goals within the framework of men's health to improve quality of life and optimize overall health outcomes

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Dannemiller and CogniMed Inc. Dannemiller is accredited by the ACCME to provide continuing medical education for physicians.

Dannemiller designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

There is no charge for this activity. Statements of Credit will be provided by e-mail following activity participation and upon completion and electronic submission of the posttest and evaluation to Dannemiller. A link to the evaluation form is provided upon completion of the activity. If you have any questions about your certificate, please e-mail cme@dannemiller.com.

To resolve identified/potential conflicts of interest, the educational content was fully reviewed by a physician member of the Dannemiller Clinical Content Review Committee who have no financial relationships with commercial interests. The resulting certified activity was found to provide educational content that is current, evidence based and commercially balanced.

It is the policy of Dannemiller to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty participating in sponsored programs are expected to identify and reference off-label product use and disclose any significant relationships with those supporting the activity or any others whose products or services are discussed. The faculty for this activity have disclosed that there will be discussion about the use of products for non–FDA-approved indications.

In accordance with the Accreditation Council for Continuing Medical Education standards, parallel documents from other accrediting bodies, and Dannemiller policy, the following disclosures have been made:

Dannemiller Staff
Bernard M. Abrams, MD, Medical Director, has nothing to disclose.
Michelle Montgomery, Director of Continuing Education, has nothing to disclose.

CogniMed Inc. Staff
Roseann MacLachlan, Senior Program Manager, has nothing to disclose.
Estelle Perera, Director, Scientific Affairs, and Medical Writer, has nothing to disclose.
Elizabeth Stanton, Editor, has nothing to disclose.

Adrian S. Dobs, MD, MHS, receives research support from Clarus Therapeutics, Endo Pharmaceuticals, the National Institutes of Health, and Takeda Pharmaceutical Company Limited.

Abraham Morgentaler, MD, receives research support from Auxilium Pharmaceuticals, Inc.; Endo Pharmaceuticals; GlaxoSmithKline; and Slate Pharmaceuticals, Inc. He is a consultant for and/or serves on the advisory boards of Abbott Laboratories, Endo Pharmaceuticals, Pfizer Inc., and Slate Pharmaceuticals, Inc.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of Dannemiller and/or its agents. As in all educational activities, we encourage the practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. Dannemiller disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

This activity is supported by an independent educational grant provided by Endo Pharmaceuticals.

This activity is an enduring material and consists of online videos. Successful completion is achieved by viewing the material, reflecting on its implications in your practice, and completing the assessment component.

The estimated time to complete this activity is 1.5 hours.

This activity was originally released December 28, 2012, and is eligible for credit through December 28, 2013.

These videos were reviewed by an impartial content reviewer and by faculty members. Faculty have final editorial control over the piece.

© 2012 CogniMed Inc. All rights reserved.                    TU14143                              December 2012